Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

327.31 -1.38 (-0.42%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
News headline image
1 Safe-and-Steady Stock to Keep an Eye On and 2 We Question
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Amgen (AMGN): Buy, Sell, or Hold Post Q3 Earnings?
Amgen’s 17.6% return over the past six months has outpaced the S&P 500 by 6.3%, and its stock price has climbed to $328.43 per share. This was partly due to its solid quarterly results, and the... 
Via StockStory
Topics Stocks
News headline image
The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance
As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of... 
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
3 Profitable Stocks with Competitive Advantages
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting... 
Via StockStory
News headline image
Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026
As investors close the books on 2025, a year defined by the continued—yet tiring—dominance of artificial intelligence and mega-cap technology, the financial community is turning its gaze toward a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill
Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the... 
Via PredictStreet
Topics Economy Intellectual Property World Trade
News headline image
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments... 
Via PredictStreet
Topics Economy Government Intellectual Property
News headline image
The Atomic Architect: How University of Washington’s Generative AI Just Rewrote the Rules of Medicine
In a milestone that many scientists once considered a "pipe dream" for the next decade, researchers at the University of Washington’s (UW) Institute for Protein Design (IPD) announced in late 2025 the... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era
Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company... 
Via PredictStreet
Topics Economy
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
SCHD vs. NOBL: Different Paths to Dividend Stability ↗
Both ETFs target dividend paying stocks, but their rules determine whether investors receive higher income or stricter dividend consistency 
Via The Motley Fool
Topics ETFs
News headline image
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief. 
Via Stocktwits
Topics Government World Trade
News headline image
The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era
As the final weeks of 2025 unfold, the biotechnology sector is undergoing a fundamental transformation, shifting from a pure-play innovation market to one increasingly dictated by the "physical"... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗
This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Investors Rotate Out of Big Tech and AI: A Market Reassessment Underway
As late 2025 draws to a close, a significant recalibration is underway in global financial markets, with investors increasingly rotating capital away from the once-dominant Big Tech and Artificial... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing. 
Via Stocktwits
Topics Government World Trade
News headline image
Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026? ↗
Each company has a bullish case, but three stand out as great long-term buys. 
Via The Motley Fool
Topics Bonds Economy Intellectual Property
News headline image
“Buying the Dip” in 2025: A Strategy Rewarded, But Future Requires Caution and Diversification
December 16, 2025 – The "buying the dip" investment strategy, which involves purchasing an asset after its price has declined with the anticipation of a subsequent recovery, has seen significant... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most ↗
Via MarketBeat
News headline image
7 Dividend ETFs to Buy With $2,000 and Hold Forever -- Including the Schwab U.S. Dividend Equity ETF (SCHD) ↗
It's hard to beat dividend-paying stocks -- in part because they tend to increase their payouts regularly. 
Via The Motley Fool
Topics ETFs
News headline image
1 Dow Jones Stock Worth Your Attention and 2 We Brush Off
The Dow Jones (^DJI) is made up of 30 of the most established and influential companies in the market. But even blue-chip stocks can struggle - some are dealing with slowing growth, outdated business... 
Via StockStory
Topics Stocks
News headline image
2 Dividend Stocks to Double Up on Right Now ↗
These dividend growth machines could have considerable upside for long-term investors. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Manufacturing Renaissance Fuels Job Market Amidst Shifting Sands
The American labor market is experiencing a fascinating dichotomy as it navigates late 2024 and 2025. While overall job creation has shown signs of moderation and significant revisions to earlier... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
2 Momentum Stocks for Long-Term Investors and 1 We Brush Off
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
News headline image
Gapping S&P500 stocks in Friday's session ↗
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session. 
Via Chartmill
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
Via Investor Brand Network
Topics Government
News headline image
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
From BioMedWire
Via GlobeNewswire
News headline image
3 Top ETFs I Plan to Pile Into in December to Boost My Passive Income in 2026 ↗
These ETFs can provide me with lots of passive income. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'? ↗
Shares crashed Tuesday on what one analyst called an "overreaction" to the company's prostate cancer treatment update. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.